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The recent discovery that normal and neoplastic
epithelial cells re-enter the stem cell state raised
the intriguing possibility that the aggressiveness of
carcinomas derives not from their existing content
of cancer stem cells (CSCs) but from their proclivity
to generate new CSCs from non-CSC populations.
Here, we demonstrate that non-CSCs of human
basal breast cancers are plastic cell populations
that readily switch from a non-CSC to CSC state.
The observed cell plasticity is dependent on ZEB1,
a key regulator of the epithelial-mesenchymal transi-
tion. We find that plastic non-CSCs maintain the
ZEB1 promoter in a bivalent chromatin configuration,
enabling them to respond readily to microenviron-
mental signals, such as TGFb. In response, the
ZEB1 promoter converts from a bivalent to active
chromatin configuration, ZEB1 transcription in-
creases, and non-CSCs subsequently enter the
CSC state. Our findings support a dynamic model
in which interconversions between low and high
tumorigenic states occur frequently, thereby in-
creasing tumorigenic and malignant potential.
INTRODUCTION
Metastatic dissemination and disease relapse are critical deter-
minants of cancer prognosis. The mechanisms underlying both
processes remain poorly understood. Recent advances in
understanding cellular hierarchies present within a variety of
tumors have changed our perspective of neoplastic cell popula-
tion organization. In particular, cell-surface antigenmarkers have
revealed distinct subpopulations of neoplastic cells within
tumors, showing pronounced differences in tumor-initiating
and metastatic powers (Visvader and Lindeman, 2012). Such
evidence indicates that, within individual tumors, geneticallyidentical cancer cells may nonetheless reside in distinct pheno-
typic states.
Importantly, tumors derived from implanting highly tumori-
genic subpopulations of cells exhibit the phenotypic heteroge-
neity of their predecessor tumors in that they contain both highly
and weakly tumorigenic cells (Visvader and Lindeman, 2012).
Implicit is the notion that highly tumorigenic cells can self-renew
and also divide asymmetrically into daughter cells with low
tumorigenic potential. Parallels identified with cell hierarchies
operating in normal adult tissues have led to coining of the
term ‘‘cancer stem cell’’ (CSC) to describe the subset of
neoplastic cells that reside in a highly tumorigenic state.
The simplest depiction would portray CSCs as residing at the
apex of a cellular hierarchy and spawning, in a unidirectional
manner, more differentiated non-CSC progeny. Cells in a num-
ber of cancer types conform to that model (Bonnet and Dick,
1997; Visvader and Lindeman, 2012). These studies imply that,
once a CSC has exited the CSC state, it cannot re-enter it.
This principle of unidirectionality holds great importance, given
the significance of CSCs for cancer development and, quite
possibly, progression to metastatic disease.
A small number of studies now suggest that not all cancers
strictly conform to the unidirectional hierarchical CSC model.
We and others have recently demonstrated that non-CSCs can
acquire CSC-like activity under certain conditions (Chaffer
et al., 2011; Gupta et al., 2011; Roesch et al., 2010). These
studies open the door to the possibility that there is likely to be
greater plasticity in cancer cell populations—yielding bidirec-
tional interconversions between CSC and non-CSC states—
than is depicted in the simplest version of the CSC model.
It has remained unclear whether these interconversions are
confined to specific types of cancer, how frequently they occur
in vivo, and how they are achieved mechanistically. These inter-
conversions are potentially important for cancer diagnosis, prog-
nosis, and therapy, given the now-extensive evidence that CSCs
are intrinsically more prone to disseminate and, at the same time,
exhibit resistance to many existing antitumor therapies (Dean
et al., 2005; Malanchi et al., 2012). In the present study, we
aimed to address the role of non-CSC-to-CSC conversions byCell 154, 61–74, July 3, 2013 ª2013 Elsevier Inc. 61
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Figure 1. Basal Breast Cancer CD44lo Non-CSC Cell Populations
Spontaneously Switch to a CD44hi CSC State In Vivo
(A) Tumorigenicity of FACS-purified luminal BrCa CD44lo cells or basal BrCa
CD44lo and CD44hi cell populations following orthotopic injection into NOD/
SCID mice (nR 6/group).
(B) Representative FACS plots for CD44 expression and quantification of
CD44hi cells generated from luminal or basal CD44lo-derived tumors
generated in (A).
(C) Basal CD44lo-digested tumors from (B) were cultured in vitro to generate
ex vivo cell lines (ExV). ExV lines were purified by FACS into CD44lo and CD44hi
components and were injected orthotopically into NOD/SCID mice (n R
8/group). Tumor incidence displayed as percentages on the graph.
Data are represented as mean ± SEM. See also Figure S1 and Tables S1–S4.
62 Cell 154, 61–74, July 3, 2013 ª2013 Elsevier Inc.determining their frequency in a cohort of breast cancer (BrCa)
cell lines.
In fact, we find that non-CSC-to-CSC conversions occur
frequently in certain subtypes of BrCa, but not in others, and
have uncovered a mechanism governing this transition. From a
therapeutic standpoint, the plasticity that we describe suggests
efforts to improve therapeutic outcome for cancer patients by
specifically targeting CSCs must be further enhanced by
coupling them with strategies designed to eliminate non-CSC-
to-CSC interconversions or, at the very least, to eliminate the
subpopulations of non-CSCs that are poised to become CSCs.
RESULTS
CD44 Status and Tumorigenic Potential
Cell-surface antigens, such as CD44, CD24, and ESA, have been
successfully used to isolate CSC-like populations from BrCa cell
lines and primary tissues. Among these antigens, it is widely
accepted that breast CSCs are contained exclusively in the
CD44hi cell compartment (Al-Hajj et al., 2003; Fillmore and
Kuperwasser, 2008; Mani et al., 2008; Visvader and Lindeman,
2012).
To test the notion that CD44hi status on its own would allow
enrichment of CSCs from BrCa cell lines, we analyzed five basal
BrCa lines (SUM149, SUM159, HCC38, HMLER, and BPLER)
and three luminal BrCa lines (MCF7, MCF7R, and T47D). (In
the clinic, luminal BrCa generally are less aggressive and hold
a better prognosis, whereas basal BrCa behave in the opposite
fashion.) CD44hi and CD44lo populations were evident to various
extents in all basal BrCa lines examined, whereas all luminal
BrCa lines consisted only of CD44lo populations (Figure S1A
available online and data not shown). To compare the relative
tumorigenic potentials of these subpopulations, we purified by
fluorescence-activated cell sorting (FACS) CD44lo fractions
from the luminal lines and CD44lo and CD44hi populations from
the basal lines. Purified populations were injected immediately
into the mammary fat pads of NOD/SCID mice. In all of these ex-
periments, cell populations were only implanted in hosts if they
were greater than 99.7% pure as judged by FACS (Figures
S1A–S1C).
We found that CD44lo luminal lines required more cells
and longer incubation times in vivo to generate tumors
of equivalent size to those seeded by purified CD44lo basal lines
(luminal, 1 3 106 cells and 12–16 weeks in vivo; basal, 5 3 105
cells and 6–10 weeks in vivo; Figure 1A and Table S1). In
addition, basal CD44hi-derived tumors were 3- to 40-fold larger
than their CD44lo counterparts when equal cell numbers were in-
jected (Figure 1A and Table S2). Limiting dilution analysis
showed that basal CD44hi cell fractions were significantly en-
riched for CSC frequency compared to their CD44lo counterparts
(10-fold, Figure S1D and Table S3). These data demonstrate
that CD44hi expression enriches for cells that naturally reside in
basal BrCa cell lines and possess higher intrinsic tumor-initiating
and growth potential. Moreover, they raised the question of how
certain BrCa populations that apparently lacked all traces of
tumor-initiating CSCs were able to generate tumors when in-
jected into host mice.
CD44hi CSCs Arising fromBasal CD44lo Cell Populations
In Vivo
In previous work, we demonstrated that non-CSCs derived from
experimentally transformed human mammary basal epithelial
cells (HMECs) could spontaneously generate de novo CSCs
both in vitro and in vivo (Chaffer et al., 2011). In the present
work, we first undertook to test the idea that non-CSC-to-
CSC conversions occur frequently in a broad array of BrCa cell
lines.
Accordingly, we used FACS to analyze the tumors described
above that arose from basal or luminal CD44lo cells. We found
that luminal CD44lo-derived tumors comprised almost entirely
CD44lo cells with a small but detectable subpopulation (average,
<0.32%) of CD44hi cells. This suggested that luminal BrCa cells
apparently lacking CD44hi tumor-initiating cells were nonethe-
less able to seed tumors by generating new CD44hi cells, albeit
at a low frequency. In marked contrast to the behavior of luminal
cells, basal CD44lo-derived tumors contained CD44hi subpopu-
lations ranging in size from 2%–22% of tumor cells (Figure 1B).
These findings indicate that basal CD44lo populations efficiently
generate CD44hi populations in vivo, whereas luminal CD44lo
populations do so with dramatically lower efficiency.
Functional Analysis of CD44hi Cells Created In Vivo
We next sought to demonstrate that CD44hi cells arising in vivo
from basal CD44lo cells were functionally equivalent to CSCs
that are naturally present in basal BrCa cell lines. To begin, we
derived several cell lines from tumors arising from implanted
CD44lo basal cells (SUM149-, SUM159- and BPLER-CD44lo
tumors) depicted in Figure 1A, terming them ExV (reflecting their
ex vivo derivation). Each of these tumor-derived ExV-cell lines
contained both CD44lo and CD44hi cells (Figure 1B), which we
termed ExV-CD44lo and ExV-CD44hi cells. We then used FACS
to isolate pure (>99%) populations of ExV-CD44lo and ExV-
CD44hi cells and immediately injected them orthotopically into
NOD/SCID mice (Figures 1C and S1E–S1G). In most cases,
ExV-CD44hi cells generated 13- to 23-fold larger tumors com-
pared to their ExV-CD44lo counterparts (SUM159 and BPLER
ExV lines) and displayed increased tumor-initiating ability
(SUM159 and SUM149 ExV lines) (Figure 1C and Table S4).
These results illustrate that CD44hi cells arising in vivo from basal
CD44lo cells behave much like the CSCs that are naturally pre-
sent in basal BrCa cell populations in that they exhibit higher
tumor-initiating and tumor growth potential than their CD44lo
counterparts.ZEB1 Drives CD44lo-to-CD44hi Cellular Plasticity
We then undertook to shed light on the mechanism(s) enabling
the observed in vivo CD44lo-to-CD44hi conversions. Given the
inherent difficulties of uncovering thesemechanisms in an in vivo
setting, we first sought mechanistic insights from an in vitro
model system that we had previously developed in which non-
transformed basal mammary epithelial cells (HME-flopc cells)
spontaneously undergo CD44lo-to-CD44hi conversions with
high frequency (Chaffer et al., 2011). As demonstrated at the
time, conversions of nontransformed immortalized human
mammary epithelial cells closely paralleled the behavior of their
corresponding transformed derivatives.
In this instance, we also drew from earlier work demonstrating
that CD44hi stem-like cells (SC) are more mesenchymal than
their CD44lo counterparts (Chaffer et al., 2011; Mani et al.,
2008). This and subsequent work (Guo et al., 2012) demon-
strated that passage through the cell-biological program
termed the epithelial-mesenchymal transition (EMT) placed cells
close to the epithelial SC state. (This EMT program is largely
studied for its ability to confer mesenchymal traits on epithelial
cells.) Accordingly, we purified CD44lo and CD44hi subpopula-
tions from HME-flopc cells and confirmed that CD44hi cells,
which contained the SC-like cells, indeed resided in a more
mesenchymal state than their more epithelial CD44lo counter-
parts (Figure 2A). Subsequently, to identify a key mediator of
non-CSC-to-CSC plasticity, we analyzed the expression of
various transcription factors (EMT-TFs) known to govern the
EMT program. Here we found that ZEB1 expression was signif-
icantly higher (10-fold) in CD44hi compared to CD44lo cells
(Figure 2B).
To determine whether ZEB1 contributed in a critical way to
mediating the transition from the CD44lo to CD44hi state, we
analyzed CD44lo-to-CD44hi conversions in HME-flopc-CD44lo
cells expressing either doxycycline-inducible control or ZEB1-
targeted shRNAs. We first confirmed that, following doxycy-
cline-mediated induction, each shRNA vector was capable
on its own of achieving 80%–90% ZEB1 knockdown (ZEB1-
kd) in CD44hi cells. We also noted no differences in cell pro-
liferation between cell populations expressing the control shRNA
and those expressing shRNAs targeting ZEB1 mRNA (Figures
S2A–S2B).
We proceeded to purify CD44lo cells expressing the various
shRNA vectors by FACS, introduced them into two-dimen-
sional (2D) cultures, and used FACS to monitor resulting cul-
tures propagated in the presence or absence of doxycycline
over the next 16 days. In the continued presence of doxycy-
cline, the ability of CD44lo ZEB1-kd cells to convert into
the CD44hi state was reduced by 75% (sh1) and 67% (sh2)
relative to cultures expressing the control shRNA (Figure 2C).
However, when doxycycline was withdrawn at day 8, per-
mitting cells to continue growing in the absence of doxycycline
for an additional 8 days, FACS analysis showed that CD44lo
ZEB1-kd cells soon regained their ability to convert to the
CD44hi state (Figure 2C). As such, the ability of CD44lo cells
to activate ZEB1 expression appeared to be an important
determinant of their ability to enter into the CD44hi state and
thus an important determinant of cell plasticity in this model
system.Cell 154, 61–74, July 3, 2013 ª2013 Elsevier Inc. 63
Figure 2. ZEB1 Is an Essential Mediator of CD44lo-to-CD44hi Cell Transitions
(A) Western blot for markers of the epithelial (CDH1) or mesenchymal (CDH2, VIM) phenotype in immortalized humanmammary epithelial cells (HME), HME-flopc,
and single cell clones derived from HME-flopc population enriched for the CD44lo phenotype (clones F1 and F2) or CD44hi phenotype (clones F3 and F4).
(B) qPCR for EMT transcription factors and MIR200B/C in nontransformed CD44lo (HME and HME-flopc-CD44lo) or HME-flopc-CD44hi cells.
(C) FACS analysis for the ability of HME-flopc-CD44lo cells to switch to the CD44hi cell state. Cells express a doxycycline (dox)-inducible control shRNA (control)
or shRNA targeting ZEB1 (sh1 and sh2)./, no dox; +/, dox on for 8 days then removed for the remaining 8 days; +/+, dox on for the duration of the experiment.
Inhibition (%) at day 16 is also shown (*p < 0.0001, **p < 0.0008, compared to /).
(D) Purified HME-flopc-CD44lo cells treated withMIR200B/C inhibitors (I) or mimetics (M) to determine effects on switching from CD44lo to CD44hi cell state. Data
are mean ± SEM.
(E) Purified HME-flopc-CD44lo cells expressing a dox-inducible control shRNA (control) or shRNA targeting ZEB1 (sh1, sh2, or sh3) were analyzed for their ability
to switch to the CD44hi state in the presence (+) or absence (–) of dox and in response to a MIR200C inhibitor (I) or mimetic (M).
(F) Transformed HME-flopc-CD44lo cells (with SV40-Early Region and RAS oncoprotein) expressing a dox-inducible shRNA targeting ZEB1 (sh1) were analyzed
for conversion to the CD44hi state in the presence (+) or absence (–) of ZEB1 knockdown. Cells were monitored by FACS for 8 days.
Data are represented as mean ± SEM. See also Figure S2.Modulation of CD44lo-to-CD44hi Conversions by the
MIR200 Family
The expression of the ZEB1 gene is tightly regulated by an inter-
active network involving ZEB1 itself, its relative ZEB2, and mem-
bers of the MIR200 family of microRNAs (Gregory et al., 2008;
Wellner et al., 2009). Thus, ZEB1 can serve to repress expression
of the MIR200 miRNAs, whereas the latter can both inhibit the
function and/or reduce the stability of the mRNAs specifying64 Cell 154, 61–74, July 3, 2013 ª2013 Elsevier Inc.ZEB1 and ZEB2; hence, these mutually antagonistic elements
constitute a circuit that operates as a bistable switch, governing
the residence of cells in either the mesenchymal or epithelial
state. Accordingly, we confirmed that ZEB1-kd in our system re-
sulted in a decrease in ZEB2 mRNA and concomitant increases
in MIR200B and MIR200C levels (Figures S2A and S4).
In light of the mutually antagonistic actions of ZEB1 and the
MIR200 miRNAs, we determined whether addition of synthetic
inhibitors or mimetics (chemically synthesized, single-stranded,
modified RNAs) influenced spontaneous CD44lo-to-CD44hi
conversions in HME-flopc-CD44lo cells. Indeed, as we found,
miR200b or miR200c inhibitors significantly increased the rate
of CD44lo-to-CD44hi conversions (Figure 2D).
We next undertook to determine whether the ability of the
MIR200 family to affect CD44lo-to-CD44hi conversions derived
largely from modulation of ZEB1 transcript levels or, alterna-
tively, from the involvement of other MIR200 targets. Here
we found that, in the presence of ZEB1-kd, the miR200c in-
hibitor was unable to provoke a CD44lo-to-CD44hi conversion
(Figure 2E).
Together, these various results highlight two important
points: (1) ZEB1 is a key mediator of spontaneous CD44lo-to-
CD44hi conversions in nontransformed HMECs, acting through
repression of the MIR200 family and, quite possibly, other
still-unidentified targets and (2) MIR200 family modulation of
CD44lo-to-CD44hi conversion derives from effects on ZEB1
mRNA levels.
We extended these observations by examining the conse-
quences of ZEB1 knockdown in HME-flopc-CD44lo cells that
had previously been transformed with SV40-Early Region and
oncogenic RAS in vitro (Figure 2F). We found that similar dy-
namics observed previously in the untransformed HME-flopc
cells operated in their transformed derivatives.
Together, these results demonstrat that ZEB1 is a key medi-
ator of CD44lo-to-CD44hi conversions in both nontransformed
and transformed HMECs in vitro and support the previously
reported notion that the dynamics of epithelial versus mesen-
chymal plasticity are quite similar in hTERT-immortalized cells
and their transformed derivatives (Chaffer et al., 2011).
ZEB1/MIR200cAreDifferentially Expressed in BrCaCell
Populations
To determine whether ZEB1 functions as a key player in driving
BrCa cell plasticity, we assessed whether ZEB1 and MIR200
expression was indicative of the CD44lo versus CD44hi state in
a broader array of BrCa lines. To do so, we first analyzed ZEB1
protein expression in luminal, basal CD44lo, and basal CD44hi
BrCa cell lines. ZEB1 was not detected in all luminal lines;
however, in basal BrCa cell lines, ZEB1 was detectable in both
populations, being 4-fold higher in matched pairs of CD44hi
compared to CD44lo cells (Figure 3A).
Given the tight regulatory loop between ZEB1 and theMIR200
family, we next examined how ZEB1 protein levels are regulated
in these BrCa cell lines. Accordingly, we analyzed ZEB1,
MIR200B, and MIR200C mRNA expression levels. We found
that luminal lines expressed very low levels of ZEB1 mRNA
and very high levels of MIR200B/C. Conversely, basal CD44lo
cells generally expressed modest but nonetheless detectable
levels of both ZEB1 mRNA and MIR200B/C, whereas basal
CD44hi cells expressed high levels of ZEB1 mRNA and low-to-
absent MIR200B/C levels (Figures 3B and 3C). We further
confirmed that these patterns of ZEB1 andMIR200B/C differen-
tial expression were maintained in the basal ExV-CD44lo and
ExV-CD44hi cell populations (Figure S3A).
These observations demonstrate that, as predicted from their
known interactions, the expression of ZEB1 and MIR200B/Cvaries inversely in these various BrCa cell lines and that the
ZEB1 EMT-TF is expressed at far higher levels in basal BrCa
cells,which represent a classof tumors that generally carryworse
clinical prognosis. Moreover, they indicated that the expression
pattern initially observed in the HME-flopc cells lines was closely
echoed by the human basal BrCa lines examined.
Role of ZEB1-Mediated CD44lo-to-CD44hi Conversions
in Tumor Initiation and Growth
The data implicating ZEB1 in CD44lo-to-CD44hi cell plasticity
in vitro did not shed light on whether it plays a similar role in vivo,
specifically in basal BrCa cells. Consequently, we introduced the
same doxycycline-inducible control or ZEB1-targeted shRNAs
used earlier into cell populations of the HCC38 and SUM159
human breast cancer cell lines and the experimentally trans-
formed HMLER cells (Figure S3B). We confirmed that ZEB1-kd
achieved in the presence of doxycycline did not affect cell prolif-
eration rates in monolayer culture (Figure S3C). FACS-purified
CD44lo populations of control or doxycycline-induced ZEB1-kd
cells were then injected orthotopically into NOD/SCID mice
immediately following FACS purification in order to analyze the
effects of ZEB1-kd on CD44lo-to-CD44hi conversions in vivo
and on tumorigenicity. Animals were administered doxycycline
(2 g/1 L) for the duration of the experiment.
Strikingly, HMLER-CD44lo cells gave rise to tumors of 0.1 g on
average after 8–10 weeks of growth in vivo, whereas their ZEB1-
kd counterparts failed to form tumors (Figure 3D), indicating that
ZEB1-mediated CD44lo-to-CD44hi conversions were essential
for tumor-initiating potential. That is, the ability of HMLER-
CD44lo carcinoma cells to initiate tumors appeared to depend
critically on the ability of these cells to spontaneously generate
CSCs in vivo, which depended in turn on their ability to activate
expression of their own endogenous ZEB1 gene. Similar results
were obtained with HCC38-CD44lo cells. In SUM159-CD44lo
ZEB1-kd cells, tumor size was significantly decreased (0.39 g
average for controls; 0.03 g and 0.18 g on average for sh1 and
sh2, respectively), and tumor-initiating potential was decreased
from 100% in control cells to 67% in ZEB1-kd cells. Together,
these data demonstrate that the ability of CD44lo basal BrCa
cell populations to upregulate ZEB1 expression is generally a
critical determinant of their tumor-initiating potential and overall
tumor growth.
Role of ZEB1 in the CD44hi Stem Cell State
Given the importance of ZEB1 in enabling spontaneous CD44lo-
to-CD44hi conversions, we wondered whether the continued
expression of ZEB1 was required thereafter for maintenance of
the resulting CD44hi cell state; alternatively, other regulatory
loops might become activated that then obviate the need for
high ZEB1 expression for initial entrance into the CD44hi state.
Accordingly, we used FACS tomonitor the ability of purified non-
transformed HME-flopc-CD44hi cells to maintain their CD44hi
marker profile in culture over a 16 day period in the presence
or absence of ZEB1-kd. Interestingly, we found that CD44hi
ZEB1-kd cells maintained their CD44hi marker profile (Figures
4A and S4).
Next, we functionally tested the SC activity of CD44hi ZEB1-kd
cells bymammosphere-forming ability in 3D culture (Dontu et al.,Cell 154, 61–74, July 3, 2013 ª2013 Elsevier Inc. 65
Figure 3. Inhibition of CD44lo-to-CD44hi Conversions by Blocking ZEB1 Decreases Tumorigenicity
(A) Western blot comparing the expression of ZEB1 in basal BrCa cell lines (HMLER and HCC38) purified for CD44lo or CD44hi subpopulations, and luminal BrCa
cell lines (ZR-75-1, T47D, MCF7 and MCF7R). Quantification of differential ZEB1 expression in basal cell lines (n = 4).
(B) qPCR assessing ZEB1, MIR200B, and MIR200C mRNA expression in BrCa cell lines.
(C) Schematic illustrating expression of MIR200 family members and ZEB1 protein expression in basal (CD44lo and CD44hi subpopulations) and luminal BrCa
cell lines.
(D) Purified CD44lo cells from HMLER or HCC38 and SUM159 basal BrCa cell lines expressing dox-inducible control shRNA (control) or shRNA targeting ZEB1
(sh1 and sh2) were analyzed for tumorigenic potential. Final tumor mass and incidence are represented (nR 5/group).
Data are represented as mean ± SEM. See also Figure S3.2003). We found that mammosphere formation was reduced
by 80%–99% compared to control. Furthermore, addition of
miR200 inhibitors to CD44hi ZEB1-kd cells could not restore
mammosphere-forming ability (Figure 4B). Together, these
data demonstrate that ZEB1 is required for initial acquisition of66 Cell 154, 61–74, July 3, 2013 ª2013 Elsevier Inc.both CD44hi expression and stem-like activity of CD44hi cells
and subsequent maintenance of SC activity but is not required
for long-termmaintenance of high cell-surface CD44 expression.
We further examined the effect of ZEB1-kd in HME-flopc-
CD44hi cells that had been transformed by the introduction of
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Figure 4. ZEB1 Is Essential for the Stem Cell/CSC Activity of CD44hi Cells
(A) FACS analysis for CD44 expression in purified HME-flopc-CD44hi cells. Cells express a doxycycline (dox)-inducible control shRNA (control) or shRNA
targeting ZEB1 (sh1 and sh2). /, no dox; +/, dox on for 8 days then removed for the remaining 8 days; +/+, dox on for the duration of the experiment. The
percentage of spontaneously arising CD44lo cells was determined by FACS over a 16 day time period.
(B) Purified HME-flopc-CD44hi cells expressing control or shRNA-targeting ZEB1 (sh1, sh2, and sh3) were assessed for mammosphere-forming ability with
or without dox induction. Cells were treated with a MIR200C inhibitor (I) or mimetic (M). p < 0.001, two-way ANOVA followed by Tukey’s multiple comparisons
test. *, different to miR-control and miR-200c-M; **, different to miR-control and miR-200c-I.
(C) Transformed HME-flopc-CD44hi cells expressing control, sh1, or sh2 were assessed for mammosphere formation with or without dox induction (p < 0.0001,
one-way ANOVA followed by Tukey’s multiple comparisons test; *, different to sh(–)).
(D) Transformed HME-flopc-CD44hi cells (control, sh1, and sh2) were purified by FACS and implanted into the fat pad of NOD/SCID mice (n = 8/group). Tumor
weight and incidence are shown.
Data are represented as mean ± SEM. See also Figure S4.SV40-Early Region and oncogenic RAS genes, i.e., the HMLER-
flopc cells. Similarly, FACS analysis confirmed that transformed
CD44hi ZEB1-kd cells maintained their CD44hi phenotype (data
not shown). We also observed that ZEB1-kd decreased tumor-
sphere formation, an in vitro surrogate measure of CSC-like
activity (60% inhibition, p < 0.003), and significantly reduced
tumor burden in vivo (p < 0.05) (Figures 4C and 4D).
To summarize, together with our earlier results, these findings
showed that ZEB1 is required for conversion from the CD44lo toCD44hi state and also for maintenance of CD44hi stem-like/CSC-
like activity. Once cells are residing in the CD44hi state, however,
ZEB1 and CD44 expression can be uncoupled, in that cells with
ZEB1-kd functionally lose their stem-like/CSC features while still
maintaining high CD44 expression. Stated differently, these data
suggest that CD44hi cells can constitute heterogeneous cell
populations in which CD44hiZEB1+ signifies great enrichment
of cells residing in a CSC-like state, whereas CD44hi
ZEB1 signifies cells that are non-CSCs.Cell 154, 61–74, July 3, 2013 ª2013 Elsevier Inc. 67
Phenotypic Plasticity and Chromatin Configuration of
the ZEB1 Promoter
The above-described experiments provided clear indication that
ZEB1 function is necessary for the generation of CD44hi stem-
like cells from CD44lo cells. Still, these observations did not pro-
vide insight into why ZEB1 was readily induced in basal CD44lo
cells but not in luminal CD44lo cells. We reasoned that current
models of epigenetic regulation might illuminate these differ-
ences in behavior, as global epigenetic differences have been
observed between luminal and basal-type BrCa (Maruyama
et al., 2011). More specifically, we chose to use chromatin immu-
noprecipitation followed by quantitative real-time PCR (ChIP-
qPCR) to examine the chromatin state at the ZEB1 promoter.
The functional state of chromatin has been defined largely by
patterns of covalent modifications to the N-terminal domains of
histones and is indicative of transcriptional activity. Thus, trime-
thylation of lysine 4 of the histone H3 subunit (H3K4me3) is
associated with transcriptional initiation (Guenther et al., 2007),
dimethylation of lysine 79 of the same subunit (H3K79me2)
is associated with transcriptional elongation (Mueller et al.,
2007), and the combination of H3K4me3 and H3K79me2 indi-
cates an actively transcribed gene. In contrast, trimethylation
of lysine 27 (H3K27me3) is often associated with transcriptional
repression mediated by the Polycomb group of proteins (Cao
et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002; Mu¨ller
et al., 2002).
In embryonic stem (ES) cells, the promoters of many genes
encoding key developmental regulators are associated with
both the permissive H3K4me3 and the restrictive H3K27me3
modifications (yielding so-called ‘‘bivalent’’ domains) (Bernstein
et al., 2006). This bivalent chromatin is thought to keep these
genes repressed but nonetheless poised for rapid transcriptional
activation in response to subsequent signaling decisions favor-
ing differentiation. These findings indicate that this combination
of histonemodificationsmay be a signature of regulators that are
required to rapidly switch cell state. Indeed, through publically
available databases, we determined that ZEB1 maintains a biva-
lent chromatin configuration in ES cells (Figure S5A).
We speculated that ZEB1 might exhibit a bivalent chromatin
state in those cells in which it was possible to switch between
low and high ZEB1 expression. To pursue this notion, we first
analyzed purified CD44lo or CD44hi HME-flopc populations.
CD44hi cells displayed chromatinmethylation patterns indicating
active transcription at the ZEB1 promoter, as determined by
the presence of both H3K4me3 and H3K79me2 marks (Figures
5A and 5B). In contrast, we found that CD44lo cells exhibited
bivalent chromatin methylation patterns at the ZEB1 promoter,
as determined by the presence of both H3K4me3 and
H3K27me3. These data indicate that immortalized untrans-
formed basal mammary epithelial cells with the ability to sponta-
neously switch to a CD44hi stem-like state do indeed maintain
their ZEB1 promoter in a poised, bivalent configuration.
We wished to extend these observations to human BrCa cell
lines, including luminal, basal CD44lo, and basal CD44hi cell pop-
ulations. Our previous data had shown that luminal cell lines ex-
press very low levels of ZEB1 mRNA (Figures 3A and 3B).
Perhaps unsurprisingly, we found that all luminal cell lines
exhibited only repressive chromatin methylation patterns at68 Cell 154, 61–74, July 3, 2013 ª2013 Elsevier Inc.ZEB1, as determined by the presence of H3K27me3 and
the relative absence of both H3K4me3 and H3K79me2 (Fig-
ure 5C). Further, we found that the chromatin at the ZEB1
promoter in basal CD44hi cells is characterized by the presence
of H3K4me3 and H3K79me2 and the relative absence of
H3K27me3, indicating active transcription. These chromatin
modifications conform with our earlier expression data, indi-
cating that all basal CD44hi cells express high levels of ZEB1
(Figures 3A–3C).
Provocatively, we found that the ZEB1 promoter in basal
CD44lo BrCa cells resided in a bivalent chromatin state in which
both H3K4me3 and H3K27me3 modifications were detected,
much as we had found in the immortalized CD44lo HME cells.
To demonstrate that both histone modifications reside simulta-
neously in specific regions in the basal CD44lo BrCa cells, we
performed sequential-ChIP analysis for H3K4me3 followed by
H3K27me3 ChIP, as well as the reverse ChIP experiment (Fig-
ure S5B). Together, these results demonstrate that both immor-
talized and neoplastic basal CD44lo populations maintain ZEB1
in a unique bivalent chromatin state poised for activation and
provide a mechanistic insight as to why ZEB1 is readily induced
in basal CD44lo cells, but not in luminal CD44lo cells, which
maintain the ZEB1 promoter in a repressed state.
Microenvironmental Stimuli and CD44lo-to-CD44hi
Conversions
Extensive evidence indicates that activation of the EMT program
and entrance into a stem cell state is generally triggered by
contextual signals received by normal and neoplastic epithelial
cells (Mani et al., 2008; Thiery et al., 2009). Among these signals,
TGFb has been shown to potently upregulate ZEB1 expression
(Gregory et al., 2011). Accordingly, we examined whether
TGFb could enhance the spontaneous CD44lo-to-CD44hi transi-
tions of immortalized HMECs. Indeed, TGFb induced a dose-
dependent increase, whereas the SB431542 TGFb receptor
inhibitor inhibited such conversions. In the context of ZEB1-kd,
however, the ability of TGFb to induce transitions was abolished
(Figures 6A and S6A and S6B). Similarly, we also found that
transformed HME-flopc-CD44lo cells could not transition from
the CD44lo to CD44hi state in response to TGFb if ZEB1 expres-
sion was inhibited (Figure 6B). Hence, TGFb can enhance
CD44lo-to-CD44hi transitions in both normal and transformed
cells in a fashion that is dependent upon induction of ZEB1.
To further confirm that TGFb-driven CD44lo-to-CD44hi conver-
sions were achieved through ZEB1, we showed that ZEB1
mRNA was induced and inhibited by TGFb and SB431542 treat-
ment, respectively (Figure S6C). As controls, we found that TGFb
target genes (PAI-1 and GADD45B) were induced and repressed
in these cells in response to modulation of TGFb signaling (Fig-
ure S6C), confirming that, overall, TFGb signaling operated in
these cells as anticipated.
We extended these findings to a series of human BrCa cell
lines and speculated that basal CD44lo cells, but not luminal
CD44lo cells, would readily transit to a CD44hi state in response
to TGFb. To test this notion, luminal (MCF7Ras and ZR-75-1)
and basal (HMLER and HCC38) CD44lo cells were treated for
4 days with TGFb (2 or 20 ng/ml). FACS analysis at day 4 showed
that the luminal cells did not generate any CD44hi cells in
Figure 5. The ZEB1 Promoter Is Maintained in a Bivalent Chromatin State in Basal CD44lo Non-CSCs
(A) Schematic showing the location of primer sets used for ChIP-qPCR.
(B and C) ChIP-qPCR for the H3K4me3, H3K27me3, and H3K79me2 histone modifications at the ZEB1 promoter in (B) nontransformed CD44lo or CD44hi cells
and (C) luminal CD44lo cells and basal CD44lo and CD44hi sorted populations.
Data are mean ± SEM of biological duplicates performed as technical replicates. See also Figure S5.response to TGFb treatment, whereas the basal CD44lo cells
responded in a dose-dependent manner to TGFb by gener-
ating CD44hi cells (Figure 6C). We further demonstrate that
TGFb stimulation led to an increase in ZEB1 protein levels (Fig-
ure S6E). Together, these data indicate that one important
contextual signal, TGFb, enhances the rate of CD44lo-to-
CD44hi transitions in basal breast cancer CD44lo cell populations
and that this response is dependent upon induction of ZEB1
expression.
Modulation of the Chromatin Status at the ZEB1
Promoter by TGFb
Having shown that TGFb induces CD44lo-to-CD44hi conversions
in basal CD44lo cells, we examined whether this effect coincided
directly with changes in the histone modification patterns at
the ZEB1 promoter. To do so, we performed ChIP-qPCR on
basal HME-flopc-CD44lo cells expressing doxycycline-inducible
ZEB1-shRNA treated with control (HCl), TGFb (2 ng/ml), or the
SB431542 TGFb receptor inhibitor (10 mM).To maintain a homogeneous CD44lo population, performing
this experiment in a ZEB1-kd intracellular environment was
essential; otherwise, TGFb treatment would cause the CD44lo
cells to transition to a CD44hi state, in which case, the CD44hi
cells harboring active histone modifications at the ZEB1
promoter would mask any changes occurring specifically in
CD44lo cells.
ZEB1 knockdown in basal CD44lo cells was induced by
exposure to doxycycline for 5 days, and cells were subse-
quently treated with TGFb, SB431542, or control (PBS
or DMSO). After an additional 5 days in the continued
presence of doxycycline, FACS analysis confirmed that the
CD44lo-ZEB1-kd cells remained as pure CD44lo populations
(Figure 6D).
We then performed ChIP-qPCR at the ZEB1 promoter to
compare changes in the levels of histonemodifications in control
versus TGFb or SB531542 treatment. Though no significant dif-
ferences in the H3K4me3 or H3K79me2 methylation patterns
were observed across all treatment groups, we found thatCell 154, 61–74, July 3, 2013 ª2013 Elsevier Inc. 69
Figure 6. TGFb Can Induce CD44lo-to-
CD44hi Switching and Modulates the
Chromatin at the ZEB1 Promoter
(A) Purified HME-flopc-CD44lo cells expressing
dox-inducible shRNA targeting ZEB1 (sh1 and
sh2) were monitored by FACS for their ability
to switch to the CD44hi state following TGFb
treatment in vitro. *p < 0.0001, different to control;
**p < 0.001, different to control (–dox).
(B) Transformed HME-flopc-CD44lo cells ex-
pressing sh1-targeting ZEB1 were treated with
TGFb and monitored by FACS for switching to the
CD44hi state.
(C) Purified CD44lo cells from luminal (MCF7R and
ZR-75-1) and basal (HMLER and HCC38) BrCa
cell lines monitored by FACS for switching to the
CD44hi state following TGFb or SB431542 treat-
ment in vitro. *p < 0.0001; two-way ANOVA fol-
lowed by Tukey’s multiple comparisons test.
(D) Representative FACS plots of HME-flopc-
CD44lo cells expressing sh1- or sh2-targeting
ZEB1 treated with control (PBS), TGFb (2 ng/ml),
or SB431542 (10 mM).
(E) ChIP-qPCR for the H3K4me3, H3K27me3, and
H3K79me2 histone modifications at the ZEB1
promoter in cells from (D) (*p < 0.0001, n = 4, two-
way ANOVA followed by Tukey’s multiple com-
parison test, different to control and SB431542).
(F–H) MCF7R cells expressing a dox-inducible
empty vector (control) or ZEB1 overexpression
construct were treated with dox and monitored
by FACS for their ability to switch to the CD44hi
state (F), for the ability to form tumorspheres
in vitro (*p < 0.0001; one-way ANOVA and
Tukey’s multiple comparisons test), different
to control (G), and for tumorigenicity in vivo
(tumor-initiating ability marked as percentages
on each bar; *p = 0.03; one-way ANOVA and
Tukey’s multiple comparisons test), different to
control and ZEB1-lo (H).
Data are represented as mean ± SEM. See also
Figure S6.TGFb treatment did indeed lead to a marked decrease in the
repressive H3K27me3 mark associated with the ZEB1 promoter
in basal CD44lo cells (Figure 6E). Together, these data demon-
strate that TGFb enables cells to transition from the bivalent
chromatin status to the active chromatin state at the ZEB170 Cell 154, 61–74, July 3, 2013 ª2013 Elsevier Inc.promoter—doing so, at least in part,
through the removal of the H3K27me3
repressive mark.
Wishing to put into context these
changes in the histone modifications at
the ZEB1 promoter, we also followed
changes in histone marks following
control, TGFb, or SB531542 treatment
at the promoters of two TGFb-respon-
sive genes (GADD45B, PAI-1) and a
TGFb-nonresponsive gene (HPRT1). We
found that the magnitude of changes
in histone modifications causing activetranscription at known TGFb target genes closely correlates
with the changes that we had previously observed at the ZEB1
promoter in response to TGFb treatment (Figure S6D). These
data provide further evidence that ZEB1 is a bona fide TGFb
target gene in these cells.
Intrinsic Responsiveness of Luminal BrCa Cells to
Exogenous ZEB1
Knowing that luminal cells are indeed responsive to TGFb
treatment (as determined by TGFb-mediated upregulation of
pSMAD2; Figure S6E), we reasoned that the inability of luminal
cells to undergo a CD44lo-to-CD44hi switch in response to
TGFb treatment might be due to their inability to activate ZEB1
transcription or, quite possibly, to an intrinsic lack of responsive-
ness of these cells to ZEB1 signaling. To explore these alterna-
tives, we forced expression of ZEB1 in MCF7Ras cells (Fig-
ure S6F). We observed a progressively increasing population
of CD44hi cells in MCF7R-ZEB1 cells over a 2 week time course
(Figure 6F). Furthermore, we found that ZEB1 overexpression
increased tumorsphere formation in vitro and tumorigenicity
in vivo in a dose-dependent manner (Figures 6G and 6H). These
data indicate that, although the endogenous ZEB1 promoter in
these luminal cells is repressed, it is nevertheless intrinsically
responsive to this EMT-TF if its expression is forced.
Assessment of ZEB1 andMIR200B/C inClinical Cases of
Breast Cancer
As described above, we found that ZEB1 pays an important role
in promoting CD44lo-to-CD44hi conversions and in maintaining
the CSC-like state in cells that already reside in the CD44hi state.
Indeed, both of these processes contribute to enhanced tumor
initiation and growth. We were interested in relating these obser-
vations to the properties of clinical cases of breast cancer. To
pursue this question, we accessed data from the Cancer
Genome Atlas Network (CGAN, 2012).
We first assessed the relative abundance of MIR200 family
members across all breast tumors represented in the CGAN
database and found that MIR200C accounts for 93% (SD =
5%) of mature miRNA in the MIR200BC family, with minority
representation of the related MIR200B (6%) and MIR429 (1%)
family members (Figure 7A); given the dominant presence of
MIR200C over its other family members, this allowed us to
focus subsequent measurements on levels of MIR200C. We
also found that the levels of ZEB1 and MIR200C expression
are inversely correlated in basal (p = 9.4 3 104; r2 = 0.13),
luminal A (p = 2.8 3 104; r2 = 0.07), and luminal B (p =
6.83 104; r2 = 0.12) subtypes, but not in HER2-overexpressing
BrCa cells (Figure 7B). We then compared the absolute abun-
dance of ZEB1 and MIR200C in BrCa subtypes and found
that, surprisingly, in contrast to the observations described
above, ZEB1 mRNA appeared to be significantly more abun-
dant in normal and luminal A BrCa subtypes compared to the
basal subtype (Figure 7C).
Given our earlier observations in cultured cells that luminal
BrCa lines do not express ZEB1 and that the chromatin at the
ZEB1 promoter resides in a repressed state in those same lines,
we reasoned that this apparent conflict with the relatively high
levels of ZEB1 and MIR200C mRNA in clinical cases of luminal
A-type BrCa might be explained in either of two ways: our
studies of cultured cancer cell lines failed to properly reflect
the behavior of corresponding cells in living tissues, or the data
in the CGAN database was confounded by strong contamination
of carcinoma cells with adjacent stromal cells expressing high
levels of ZEB1.To resolve these alternatives, we analyzed ZEB1 protein
expression in a tissue microarray of breast cancer biopsies (Fig-
ures 7D and S7). We found that ZEB1 protein is present at high
levels in the stromata of all breast cancer subtypes. Interestingly,
however, comparison of ZEB1 protein specifically in cancer cells
showed that triple-negative (TN) BrCa cells have significantly
higher levels of ZEB1 protein compared to luminal A cancer cells
(Figure 7D, p = 0.017). In fact, ZEB1 was not present in the
carcinoma cells of any luminal A BrCa sample examined (0/91
samples). From these data, we conclude that the strong
ZEB1-positive signature produced by the TCGA analysis data
in luminal A BrCa compared to TN BrCa (Figure 7C) is entirely
attributable to stromal cells present as significant contaminants
in the luminal A samples. Our data further highlight the difficulty
of interpreting such global genomic analyses performed on
whole-tumor digests, in which the relative representations of
both carcinoma cells and stromal cells cannot be accounted for.
Together with our demonstration in BrCa cell lines that
ZEB1 is the driver of the de novo generation of CSCs from
non-CSC cell populations, the high expression of ZEB1 in TN
BrCa cells raises the possibility that the more aggressive nature
of clinical TN-type BrCa compared to luminal-type BrCa may be
in part attributable to the ability of TN BrCas to readily activate
ZEB1 expression in response to microenvironmental stimuli
and, subsequently, to create a continuous source of highly
tumorigenic CSCs.
DISCUSSION
The present work reveals that the dynamics of interconversion
between epithelial non-CSC and mesenchymal/CSC states are
important determinants of normal and neoplastic epithelial tissue
behavior. In contrast to the widely accepted CSC model, in
which CSCs give rise to non-CSC progeny in a unidirectional
manner, we have demonstrated that, in certain carcinoma
subtypes—notably, basal carcinomas of the breast—neoplastic
cells can readily convert from a CD44lo to a CD44hi state (Fig-
ure 7E). Given the strong enrichment of CSCs in the CD44hi state
and their virtual absence in CD44lo cells (Al-Hajj et al., 2003), this
suggested an interconversion between non-CSCs and CSCs, as
indeed we demonstrated directly.
Our analyses indicate that this plasticity is not a universal
property of all breast carcinomas. Plastic behavior was associ-
ated with four out of five basal-type BrCa cell lines, whereas
luminal CD44lo populations (four out of four) were extremely
inefficient at switching from the CD44lo-to-CD44hi phenotype.
These findings demonstrate fundamental differences in the
biology driving basal- versus luminal-type tumors and suggest
that the well-documented aggressive behavior of basal-type
BrCas may be traced, in no small part, to this plasticity and the
associated ability to generate carcinoma cells with enhanced
tumor-initiating powers. The discovery of ZEB1, a well-charac-
terized EMT-TF, as a keymediator of CD44lo-to-CD44hi plasticity
is consistent with the idea that the epithelial-mesenchymal tran-
sition generates cells with CSC-like activity (Mani et al., 2008;
Morel et al., 2008). Although we do not rule out the possibility
that other EMT transcription factors functioning upstream of
ZEB1 may also drive non-CSC-to-CSC conversions, we haveCell 154, 61–74, July 3, 2013 ª2013 Elsevier Inc. 71
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Figure 7. ZEB1 in Clinical Cases of Breast Cancer
(A) MIR200C accounts for 93% (SD = 5%) of mature miRNA in the MIR200BC family, which also includes MIR200B (6%) and MIR429 (1%), so subsequent
analysis uses MIR200C to represent the MIR200BC family.
(B) Levels of ZEB1 andMIR200C are inversely correlated in basal (p = 9.43 104; r2 = 0.13), luminal A (p = 2.83 104; r2 = 0.07), and luminal B (p = 6.83 104;
r2 = 0.12) subtypes (but not Her2). ZEB1 is shown as median-centered values and MIR200C by log2-transformed reads per million mapped reads (RPM).
(C) mRNA abundance of ZEB1, ZEB2, andMIR200C by subtype. Asterisks indicate a difference compared to the basal subtype (p < 0.05; ANOVA with Dunnett
post hoc). *p < 0.05; **p < 0.01.
(D) Human BrCa tissue array stained with an antibody targeting ZEB1 (1003 and 4003 images provided). **p = 0.017; TN compared to luminal A, Fisher’s exact
test followed by Bonferroni correction for multiple hypothesis testing. See also Figure S7.
(E) Schematic depicting: (1) an alternative CSCmodel for basal-type BrCa that includes bidirectional conversions between CSCs and non-CSCs and (2) a model
of non-CSC-to-CSC conversion that includes a microenvironmental stimulus acting on non-CSCs harboring bivalent chromatin marks at the ZEB1 promoter,
enabling a rapid activation of ZEB1 and switch to a CSC state.
See also Figure S7.demonstrated that ZEB1 plays a critical, rate-limiting role in
governing basal BrCa cell plasticity.
We found that the chromatin configuration associated with the
ZEB1 promoter in luminal CD44lo cells was repressed, whereas
in basal CD44lo cells it was maintained in a bivalent/poised
configuration, corresponding with the respective inability and72 Cell 154, 61–74, July 3, 2013 ª2013 Elsevier Inc.ability of these two BrCa cell types to generate de novo CSC-
like cells. As we argue here, differences in chromatin configura-
tion appear to be responsible for the profound differences in cell
plasticity. This yields, in turn, the interesting notion that the
aggressiveness of certain breast carcinomas may not be deter-
mined by their steady-state concentrations of CD44hi stem-like
cells; instead, their content of non-CSC cells with a proclivity to
readily spawn CD44hi stem-like derivatives may strongly influ-
ence the overall malignant behavior of these tumors. Stated
differently, the bivalency of the ZEB1 promoter in carcinoma
cells may represent a useful prognostic parameter of tumor
aggressiveness, a notion that will require extensive clinical
testing and validation. Because such bivalent chromatin is
already present in certain immortalized, nontransformed human
mammary epithelial cells, this might suggest that the establish-
ment of such bivalency occurs during the normal ontogeny of
this lineage differentiation.
The nature of ZEB1-associated poised chromatin in basal
CD44lo cells suggests that those cells may readily and efficiently
re-enter a stem-like state, given the appropriate stimulus.
Indeed, we demonstrated that TGFb, a well-known EMT-
inducing stimulus (Gregory et al., 2011), can efficiently promote
non-CSC-to-CSC conversion. The same TGFb stimulus failed
to induce luminal CD44lo cells to convert to the CSC state (Fig-
ure 7E). Here, bivalency associated with the ZEB1 promoter per-
mits basal-type non-CSCs to respond to the same stimulus in a
qualitatively different manner than luminal type non-CSCs. In
that regard, it is plausible that basal non-CSCs located in an in-
flammatory microenvironment that is rich in EMT-inducing het-
erotypic signals may respond to local stimuli by switching to a
CD44hi CSC state; the resulting cells may then significantly
enhance the aggressiveness of the tumors in which they reside.
At present, it seems plausible that disseminating CSCs are the
principal agents of metastasis, as they are endowed with multi-
ple traits that are essential for completion of most of the steps
of the invasion-metastasis cascade (Thiery et al., 2009). How-
ever, in light of the plasticity that we can now ascribe to basal
CD44lo non-CSCs, it is conceivable that they too may leave a
primary tumor and, following arrival at secondary tissue sites,
create pools of newly formed CSCs that are critical to subse-
quent spawning of metastatic deposits. If validated, this would
suggest that certain tumors are clinically aggressive because
they can dispatch non-CSCs (which are usually far more
numerous than CSCs) to distant sites as founders of new meta-
static colonies following non-CSC-to-CSC conversions. In the
same manner, plastic basal-CD44lo cells may also contribute
to disease recurrence. These and other considerations suggest
that therapies directed at preventing non-CSC-to-CSC conver-
sions should be considered as essential components of adjuvant
therapies for breast cancer patients and, quite possibly, patients
suffering other types of neoplastic disease.EXPERIMENTAL PROCEDURES
Animals
All mouse studies were performed under the supervision of MIT’s Division of
Comparative Medicine in accordance with protocols approved by the Institu-
tional Animal Care and Use Committee. NOD/SCID mice were bred in house.
Mice were 2–4 months of age at time of injections. Tumor cells were resus-
pended in 20%Matrigel/MEGM (20 ml) for mammary fat pad injections. Tumors
were dissected at the end of the experiment and weighed. GFP-positive lung
metastases were counted from individual lobes by fluorescent microscopy.
Cell Culture
Cells were cultured as described in Table S5.Vectors and Viral Infections
pBabe SV40-ER (Zeocin), pBabe H-Ras (Puromycin), PRRL-GFP, pLV-
Tomato vectors, production of virus, and infection of target cells have been
previously described (Elenbaas et al., 2001; Shaner et al., 2004). Infected cells
were selected with Zeocin (100 mg/ml) and Puromycin (2 mg/ml). shRNA were
purchased from Open Biosystems.
RNA Preparation and qRT-PCR Analysis
Total RNA was isolated using the RNeasy Micro kit (QIAGEN). Reverse tran-
scription was performed with miScript II RT Kit; miScript and Qantitect Primer
Assays were used to detect miRNAs and mRNA (QIAGEN).
ChIP-qPCR
Chromatin immunoprecipitation was performed as previously described (Lee
et al., 2006).
Mammosphere Culture
Mammosphere culture was performed as previously described (Dontu et al.,
2003).
Statistical Analysis
Data are presented as mean ± SEM. Student’s t test was used to compare two
groups (p < 0.05 was considered significant) unless otherwise indicated.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and six tables and can be found with this article online at http://dx.doi.
org/10.1016/j.cell.2013.06.005.
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